Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAge Labs (BIOA) EPS (Weighted Average and Diluted) (2023 - 2026)

BioAge Labs' EPS (Weighted Average and Diluted) history spans 2 years, with the latest figure at -$0.72 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 104.76% to -$0.72 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.24, a 69.19% increase, with the full-year FY2025 number at -$2.24, up 66.21% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.72 in Q4 2025 for BioAge Labs, down from -$0.56 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for BIOA hit a ceiling of $15.13 in Q4 2024 and a floor of -$7.94 in Q2 2024.